US/UK/Canada

Share

Pick a time period -
Tags ( Active)

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Company Announcement June 25, 2020 at 4:00 p.m. Finnish timeThe Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 7 April 2020 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions. The amount of the shares to be issued pursuant to the authorization and the amount of the shares issued by virtue of the authorization to issue special rights entitling to shares shall not exceed

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Nanoform Finland Plc – Manager’s transactions – June 10, 2020 at 02:00 p.m. Finnish time Manager’s transaction related to Nanoform Finland Plc’s CEO Edward Hæggström’s sale of certain shares in accordance with prospectus in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020. Nanoform Finland Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Haeggström Edward Position: Chief Executive Officer Issuer: Nanoform Finland Plc LEI: 743700JJO2NU8LBS1592

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Nanoform Finland Plc – Manager’s transactions – June 10, 2020 at 02:00 p.m. Finnish time Manager’s transaction related to Nanoform Finland Plc’s CFO and member of the Board of Directors Albert Hæggström’s subscription of shares in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020. Nanoform Finland Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Haeggström Albert Position: Member of the Board/Deputy member Issuer: Nanoform Finland Plc LEI:

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Nanoform Finland Plc (“Nanoform” or the “Company”) today announced that it has today filed a listing application with Nasdaq Helsinki Ltd for listing of the Company’s shares on Nasdaq First North Premier Growth Market Finland (the “First North Premier Finland”) under the trading code “NANOFH”, maintained by Nasdaq Helsinki Ltd, and with

Nanoform and Orion collaborate on next-generation drug development

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, today announced a collaboration to apply Nanoform's award-winning CESS® technology to new chemical entities. Building on an existing relationship, this collaboration will utilize Nanoform’s proprietary CESS® technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development. Many new chemical entities struggle to progress into clinical development due to

Nanoform appoints Head of US Sales

Helsinki, Finland – Nanoform, an innovative nanoparticle medicine enabling company, has appointed Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market. As Head of US Sales, Sally Langa will drive business development in this key region. Together with the rest of the commercial team, she will introduce and accelerate growth of Nanoform’s technology platform to major Pharma and Biotech companies in the US market. Sally Langa has more than 30 years of successful track record in senior business

Nanoform wins the CPhI Excellence in Pharma Award for Formulation

Helsinki, Finland - Nanoform an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards. Receiving this highly contested prize is an acknowledgement of Nanoform’s commitment to innovation in the industry through its best-in-class CESS[®] nanonization™ technology. Nanoform has been awarded for its work helping international partners find innovative solutions for drug development and delivery. Its multi-patented nanonization processhas the ability to double the number of drug compounds reaching

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media